Effects of intraaortic balloon augmentation in a porcine model of endotoxemic shock

Resuscitation

Volumn 60, Issue 3, 2004, Pages 319-326

  Engoren, Milo ^a   Habib, Robert H ^a,b  

^a ST VINCENT MERCY MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Acidose l ctica; Bal o de contrapuls o intra aortico; Choque s ptico; Endotoxemia; Fluxo sangu neo no mioc rdio; Intraaortic balloon pump; Lactic acidosis; Myocardial blood flow; Septic shock

Indexed keywords

ENDOTOXIN; LACTIC ACID; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA BALLOON; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY SINUS; ENDOTOXEMIC SHOCK; EXPERIMENTAL MODEL; FEMALE; INFUSION; INTERMETHOD COMPARISON; MALE; MATHEMATICAL COMPUTING; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SHOCK; STATISTICAL ANALYSIS; SWINE; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; INTRA-AORTIC BALLOON PUMPING; LACTIC ACID; MALE; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SHOCK, SEPTIC; SWINE; TROPONIN I;

EID: 1842504453     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2003.10.008     Document Type: Article

References (59)

1. Parrillo J.E. Pathogenetic mechanisms of septic shock. New Engl. J. Med. 328:1993;1471-1477.
2. Artucio H., Digenio A., Pereyra M. Left ventricular function during sepsis. Crit. Care Med. 17:1989;323-327.
3. Parker M.M., Ogbibene F.P., Parrillo J.E. Peak systolic pressure/end-systolic volume ration, a load-independent measure of ventricular function, is reversibly decreased in human septic shock. Crit. Care Med. 22:1994;1955-1959.
4. Parker M.M., Shelhamer J.H., Bacharach S.L.et al. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med. 100:1984;483-490.
5. Hotchkiss R.S., Sheng-Kwei S., Neil J.J.et al. Sepsis does not impair tricarboxylic cycle in the heart. Am. J. Physiol. 260:1991;C50-C57.
6. Keller R.S., Jones J.J., Kim K.F.et al. Endotoxin-induced myocardial dysfunction: is there a role for nitric oxide? Shock. 4:1995;338-344.
7. Kraut E.J., Chen S., Hubbard N.E., Erickson K.L., Wisner D.H. Tumor necrosis factor depresses myocardial contractility in endotoxemic swine. J. Trauma. 46:1999;900-906.
8. Bloos F.M., Morisaki H.M., Neal A.M.et al. Sepsis depresses the metabolic oxygen reserve of the coronary circulation in mature sheep. Am. J. Respir. Crit. Care Med. 153:1996;1577-1584.
9. Cunnion R.E., Schaer G.L., Parker M.M., Natanson C., Parrillo J.E. The coronary circulation in human septic shock. Circulation. 73:1986;637-644.
10. Arlati S., Brenna S., Prencipe L.et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 26:2000;31-37.
11. Hotchkiss R.S., Karl I.E. Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. J. Am. Med. Assoc. 267:1992;1503-1510.
12. Hotchkiss R.S., Rust R.S., Dence C.S.et al. Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F] fluoromisonidazole. Am. J. Physiol. 261:1991;R965-R972.
13. Solomon M.A., Correa R., Alexander H.R.et al. Myocardial energy metabolism and morphology in a canine model of sepsis. Am. J. Physiol. 266:1994;H757-H768.
14. Crouser E.D., Julian M.W., Blaho D.V., Pfeiffer D.R. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit. Care Med. 30:2002;276-284.
15. Boulos M., Astiz M.E., Barua R.S., Osman M. Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit. Care Med. 31:2003;353-358.
16. Hersch M., Gnidec A.A., Bersten A.D., Troster M., Rutledge F.S., Sibbald W.J. Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery. 107:1990;397-410.
17. Groeneveld A.B.J., Van Lambalgen A.A., van den Bos G.C., Bronsveld W., Nauta J.J., Thijis L.G. Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. Cardiovasc. Res. 24:1991;80-88.
18. Turner A., Tsamitros M., Bellomo R. Myocardial cell injury in septic shock. Crit. Care Med. 27:1999;1775-1780.
19. ver Elst K.M., Spapen H.D., Nguyen D.N., Garbar C., Huyghens L.P., Gorus F.K. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin. Chem. 46:2000;650-657.
20. Tuchschmidt J., Fried J., Astiz M., Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest. 102:1992;216-220.
21. Bernard G.R., Vincent J.L., Laterre P.F.et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl. J. Med. 344:2001;699-709.
22. Ziegler E.J., Fisher C.J. Jr., Sprung C.L.et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. New Engl. J. Med. 324:1991;429-436.
23. Boekstegers P., Weidenhofer S., Pilz G., Werdan K. Peripheral oxygen availability within skeletal muscle in sepsis and septic shock. Infection. 19:1991;317-323.
24. Edwards J.D. Oxygen transport in cardiogenic and septic shock. Crit. Care Med. 19:1991;658-663.
25. Parker M.M., Shelhamer J.H., Bacharach S.L.et al. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med. 100:1984;483-490.
26. Forrester J.S., Diamond G.A., Swan H.J. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am. J. Cardiol. 39:1977;137-145.
27. G-methylarginine hydrochloride 546C88. Crit. Care Med. 28:2000;1263-1268.
28. Wanecek M., Weitzberg E., Alving K., Rudehill A., Oldner A. Effects of the endothelin receptor antagonist bosetan on cardiac performance during porcine endotoxin shock. Acta Anaesthesiol. Scand. 45:2001;1262-1270.
29. Brealey D., Brand M., Hargreaves I.et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 360:2002;219-223.
30. Ishino K., Botker H.E., Clausen T., Hetzer R., Sehested J. Myocardial adenine nucleotides, glycogen, and NA, K-ATPase in patients with idiopathic dilated cardiomyopathy requiring mechanical circulatory support. Am. J. Cardiol. 83:1999;396-399.
31. De Backer D., Creteur J., Preiser J.-C., Dubois M.J., Vincent J.L. Microvascular blood flow is altered in patients with sepsis. Am. J. Respir. Crit. Care Med. 166:2002;98-104.
32. Liu P.P., Mak S., Stewart D.J. Potential role of the microvasculature in progression of heart failure. Am. J. Cardiol. 84:1999;23L-26L.
33. Sibelius U., Grandel U., Buerke M.et al. Staphylcoccal α-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts - role of thromboxane formation. Circulation. 101:2000;78-85.
34. Sibelius U., Grandel U., Buerke M.et al. Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escheria coli hemolysin in perfused rat hearts. Crit. Care Med. 31:2003;683-688.
35. Sirera R., Salvador A., Roldan I., Talens R., Gonzalez-Molina A., Rivera M. Quantification of proinflammatory cytokines in the urine of congestive heart failure patients. Its relationship with plasma levels. Eur. J. Heart Fail. 5:2003;27-31.
36. Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J.E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 183:1996;949-958.
37. Deten A., Volz H.C., Briest W., Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc. Res. 55:2002;329-340.
38. Gore J.M., Goldberg R.J., Spodick D.H., Albert J.S., Dalen J.E. A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. Chest. 92:1987;721-727.
39. Zion M.M., Balkin J., Rosenmann D.et al. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group. Chest. 98:1990;1331-1335.
40. Kovack P.J., Rasak M.A., Bates E.R., Ohman E.M., Stomel R.J. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J. Am. Coll. Cardiol. 29:1997;1454-1458.
41. Anderson R.D., Ohman E.M., Holmes D.R. Jr.et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observation from the GUSTO-I study. J. Am. Coll. Cardiol. 30:1997;708-715.
42. Analysis of repeated measures data. In: Littell RC, Milliken GA, Stroup WW, Wolfinger RD, editors. SAS Systems for Mixed Models. Cary, NC: SAS Institute; 1996.
43. The univariate procedure. In: SAS Institute, SAS Procedures Guide, version 6. 3rd ed. Cary, NC: SAS Institute; 1990.
44. Baydoun A.R., Foale R.D., Mann G.E. Bacterial endotoxin rapidly stimulates prolonged endothelium-dependent vasodilatation in the rat isolated perfused heart. Br. J. Pharmacol. 109:1993;987-991.
45. Kreimeier U., Hammersen F., Ruiz-Morales M., Yang Z., Messmer K. Redistribution of intraorgan blood flow in acute, hyperdynamic porcine endotoxemia. Eur. Surg. Res. 23:1991;85-99.
46. Raymond R.M. When does the heart fail during shock? Circ. Shock. 30:1990;27-41.
47. Pribble C.G., Shaddy R.E. Intra-aortic balloon counterpulsation in newborn lambs infected with Group B streptococcus. ASAIO Trans. 37:1991;33-37.
48. Weber K.T., Janicki J.S. Intraaortic balloon counterpulsation. A review of physiological principles, clinical results, and device safety. Ann. Thorac. Surg. 17:1974;602-636.
49. Ince C., Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit. Care Med. 27:1999;1369-1377.
50. Schwartz D.R., Malhotra A., Fink M.P. Microcirculatory weak units - an alternative explanation. Crit. Care Med. 28:2000;3127-3129.
51. Lara T.M., Wong M.S., Rounds J., Robinson M.K., Wilmore D.W., Jacobs D.O. Skeletal muscle phosphocreatine depletion depresses myocellular energy status during sepsis. Arch. Surg. 133:1998;1316-1321.
52. Fernandes C.J. Jr., Akamine N., Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med. 25:1999;1165-1168.
53. Sonntag J., Merin R.G., Donath U., Radke J., Schenk H.D. Myocardial metabolism and oxygenation in man awake and during halothane anesthesia. Anesthesiology. 51:1979;204-210.
54. Cason B.A., Verrier E.D., London M.J., Mangano D.T., Hickey R.F. Effects of isoflurane and halothane on coronary vascular resistance and collateral myocardial blood flow: their capacity to induce coronary steal. Anesthesiology. 67:1987;665-675.
55. Hoque A.M., Marczin N., Catravas J.D., Fuchs L.C. Shock. 6:1996;365-370.
56. Hansen M.K., O'Connor K.A., Goehler L.E., Watkins L.R., Maier S.F. The contribution of the vagus nerve in interleukin-1beta-induced fever is dependent on dose. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280:2001;R929-R934.
57. Borovikova L.V., Ivanova S., Zhang S.et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 405:2000;458-462.
58. Crick S.J., Sheppard M.N., Ho S.Y., Gebstein L., Anderson R.H. Anatomy of the pig heart: comparisons with normal human cardiac structure. J. Anat. 193:1998;105-119.
59. Liedtke A.J., Hughes H.C., Neely J.R. An experimental model for studying myocardial ischemia. J. Thorac. Cardiovasc. Res. 69:1975;203-211.